On September 13, 2022, the "Shengbai Oral Liquid Bone Marrow Inhibition Summit Forum • Shandong Station" hosted by Hubei Mengyang Pharmaceutical was grandly held in the cloud.

The conference was chaired by Professor Ma Xuezhen from Qingdao Central Hospital and presided over by Professor Wan Haitao from Qingdao Central Hospital. The conference invites Professor Zhao Kaihua, Professor Song Haiping, Professor Liu Shichao, Professor Zhu Chao, and Professor Liu Yuanyuan from Qingdao Central Hospital; Professor Liu Hongxun and Professor Han Minghui from West Coast Central Hospital; Professor Wang Wenhui and Professor Zhang Jianyou from Weifang People's Hospital; Professor Zhang Shixing and many other teaching experts from Weifang Second People's Hospital gathered in the cloud to jointly explore the common adverse reactions in tumor diagnosis and treatment - the pathogenesis of bone marrow suppression, the mechanism of action of Shengbai oral liquid in bone marrow suppression treatment, and its clinical effectiveness. The conference gathered numerous experts in the field of malignant tumor diagnosis and treatment, creating a strong academic atmosphere and receiving praise from multiple parties.

At the meeting, Professor Wang Wenhui from Weifang People's Hospital gave a detailed explanation on the common adverse reactions during the diagnosis and treatment of malignant tumors - the pathogenesis of bone marrow suppression. Professor Wang Wenhui mentioned that Shengbai Oral Liquid not only increases white blood cells but also has a protective effect on bone marrow hematopoietic stem cells. While restoring normal bone marrow hematopoietic function, it can also effectively treat leukopenia caused by radiotherapy and chemotherapy.

Next, Professor Zhao Kaihua from Qingdao Central Hospital shared the mechanism of action and research progress of Shengbai Oral Liquid. Professor Zhao Kaihua gave a detailed explanation of the mechanism of action of Shengbai Oral Liquid in bone marrow suppression based on modern pharmacological research results. A wonderful sharing was made on the interpretation of product prescriptions and how to apply Shengbai Oral Liquid to achieve satisfactory therapeutic effects based on the diagnosis and treatment course of radiotherapy and chemotherapy. Enable the attending experts to have a profound understanding of the effectiveness and safety of the product. The discussion guests also had wonderful discussions on the thematic content shared by Professor Wang Wenhui and Professor Zhao Kaihua.

During the case sharing session, Professor Zhang Jianyou from Weifang People's Hospital and Professor Liu Yuanyuan from Qingdao Central Hospital shared typical effective cases of Shengbai Oral Liquid in the prevention and treatment of chemotherapy induced bone marrow suppression. Based on typical case sharing and guest comments, it is concluded that prevention before radiotherapy and chemotherapy, synchronous radiotherapy and chemotherapy, and the use of Shengbai oral liquid after radiotherapy and chemotherapy can effectively reduce or improve white blood cell levels, and continuous medication has a significant therapeutic effect. Ensuring the smooth progress of radiotherapy and chemotherapy, while improving white blood cell levels, can also improve symptoms of cancer-related fatigue.

At the end of the conference, Professor Ma Xuezhen from Qingdao Central Hospital made a summary of the overall meeting. Professor Ma Xuezhen stated that during routine bone marrow suppression treatment, there is an increase in white blood cells accompanied by adverse reactions. Shengbai Oral Liquid not only enhances white blood cells but also improves symptoms of cancer-related fatigue, playing a unique role in treating bone marrow suppression.

The conference was a complete success, bringing together numerous experts in the field of cancer, presenting us with an academic feast and highlighting the effectiveness and safety of Shengshengbai Oral Liquid in clinical applications. Mengyang Pharmaceutical will also continue to work hard to improve the standardization level of malignant tumor diagnosis and treatment in China, reduce the incidence of toxic side effects related to tumor treatment, improve the quality of life of patients, and make contributions to ensuring medical safety!